Current Report Filing (8-k)
10 May 2022 - 6:13AM
Edgar (US Regulatory)
0001346830
false
0001346830
2022-05-09
2022-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 9, 2022
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36279 |
|
75-3175693 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
4 Stamford Plaza
107 Elm Street, 9th Floor
Stamford, Connecticut |
|
|
|
06902 |
(Address of principal executive offices) |
|
|
|
(Zip Code) |
|
|
|
|
|
Registrant's telephone number, including area code (203) 406-3700 |
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol |
Name
of each exchange on which registered |
Common Stock, par value $0.001 per share |
CARA |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨.
Item 2.02. |
Results of Operations and Financial Condition. |
On May 9, 2022, Cara Therapeutics, Inc. (the “Company”)
issued a press release announcing its financial results for the first quarter ended March 31, 2022. A copy of the press release is
being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference
to this Item 2.02.
The information furnished pursuant to this Item 2.02, including Exhibit
99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of
the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended,
whether made before or after the date hereof, regardless of any general incorporation language in such a filing.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CARA THERAPEUTICS, INC. |
|
|
|
By: |
/s/ Thomas Reilly |
|
|
Thomas Reilly |
|
|
Chief Financial Officer |
|
|
(Principal Financial and Accounting Officer) |
Date: May 9, 2022
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2024 to May 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From May 2023 to May 2024